Aptevo Therapeutics Inc Stock Price, News & Analysis

Aptevo Therapeutics has initiated the expansion phase of its clinical trial for APVO436, aimed at treating adult patients with acute myeloid leukemia (AML). Following a successful dose escalation phase, the new multi-center trial will enroll 90 patients across five cohorts, evaluating the drug's safety and efficacy when combined with standard treatments. Positive results from the initial phase highlighted a manageable side effect profile and no severe neutropenia, promising potential for APVO436's integration into standard AML treatments.

Aptevo Therapeutics (NASDAQ:APVO) announced results from a Phase 1 dose escalation trial of APVO436, its lead candidate for acute myeloid leukemia (AML) and myelodysplastic syndromes. The study enrolled 46 patients, demonstrating a favorable safety profile with no severe neutropenia, a common issue with CD123-targeting therapies. The trial identified an active dose for advanced studies and reported encouraging signs of clinical activity, including stabilization and complete remissions in several patients. Aptevo plans to submit the data for publication later this year.

Aptevo Therapeutics reported Q1 2021 financial results, highlighting ongoing progress in the Phase 1 trial of APVO436 for Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome. As of March 31, 2021, the company had cash and cash equivalents of $58.8 million. They received $35 million from a royalty purchase agreement with HCR and recorded $2.4 million in royalty revenue from Pfizer's RUXIENCE. However, Aptevo reported a net loss of $7.3 million, or $1.64 per share, compared to a net income of $2.9 million in Q1 2020.

Aptevo Therapeutics (NASDAQ:APVO) announced its participation at the American Association for Cancer Research Virtual Annual Meeting, showcasing two key posters from April 10-15 and May 17-21, 2021. The posters cover preclinical updates on APVO603 and APVO442. APVO603 targets both 4-1BB and OX40, demonstrating significant anti-tumor response and safety in murine studies. APVO442, a bispecific candidate, shows strong efficacy and a favorable safety profile against PSMA+ tumors. Detailed abstracts will be available in the Virtual Poster Hall, allowing for presenter interactions.

Aptevo Therapeutics (NASDAQ:APVO) announced a significant advancement in its Phase 1/1b study of APVO436 for treating acute myeloid leukemia, with ongoing enrollment in cohort 10. The 2020 financial results showed a net loss of $17.75 million, an improvement from $40.45 million in 2019. Aptevo sold the RUXIENCE royalty payment stream for $35 million, with an additional $32.5 million possible based on sales milestones. The company maintains a strong balance sheet, allowing for continued clinical development. CEO Marvin White expressed optimism regarding the company's growth prospects.

Aptevo Therapeutics Inc. (NASDAQ:APVO) announced on February 9, 2021, that it received a notice from Tang Capital Partners, LP (TCP) intending to nominate two candidates for election to the Board of Directors and to submit an advisory stockholder proposal for the upcoming 2021 Annual Meeting. The Company’s Board and management are committed to maximizing long-term stockholder value and will review the nominations and present their recommendations in a proxy statement. Stockholders are not required to take any action at this time.

Aptevo Therapeutics (NASDAQ:APVO) provided a significant update on its APVO436 Phase 1 clinical trial, revealing that patient dosing in cohorts 1-8 has been completed, with 36 patients enrolled. Encouragingly, no dose-limiting toxicities were noted in cohorts 5-8. Notably, two patients in cohort 6 achieved complete remission, highlighting potential efficacy. As the trial advances into cohort 9, Aptevo remains focused on improving patient outcomes. The company’s ADAPTIR platform continues to facilitate innovative bispecific antibody development, targeting cancers effectively.

Aptevo Therapeutics announced the launch of its new ADAPTIR-FLEX platform technology and introduced bispecific therapeutic candidate APVO442, targeting PSMA and CD3 for prostate cancer treatment. APVO442 aims to enhance binding strength to tumor antigens while maintaining a low affinity for T cells, potentially improving therapeutic outcomes. The company reported success in earlier clinical trials of its other candidate, APVO436, with two patients achieving complete remission. These advancements signify Aptevo's commitment to developing innovative immuno-oncology therapies.

Aptevo Therapeutics Inc. (NASDAQ:APVO) announced an unsolicited non-binding offer from Tang Capital Partners, LP to acquire all outstanding shares of Aptevo not already owned for $50.00 per share. The Board of Directors will evaluate this proposal while fulfilling their fiduciary duties. They caution that no decisions have been made and that there are no guarantees of an accepted definitive offer. Shareholders do not need to act at this time. Aptevo is a biotechnology company focused on developing immuno-oncology therapeutics using its ADAPTIR™ technology.